Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19

Insights into Imaging

Table 2 CT-SS according to clinical data (n = 247)

	COVID-19 LDCT		p value
	Score
	Mean ± SD
	No	Yes
Clinical data
Sex (male/female)	5.1 ± 6.9	4.0 ± 6.0	0.247
Symptoms	4.3 ± 6.4	4.5 ± 6.5	0.834
Rhinitis	4.9 ± 6.7	3.9 ± 6.1	0.223
Fever	4.1 ± 6.4	6.9 ± 6.2	0.002
Anosmia	5.2 ± 7.3	3.7 ± 5.2	0.342
Ageusia	4.6 ± 6.8	4.4 ± 6.0	0.805
Dyspnea	3.5 ± 5.3	7.2 ± 8.3	< 0.001
Chest pain	4.6 ± 6.7	4.0 ± 5.1	0.89
Needed oxygen	4.0 ± 5.8	20.9 ± 7.9	< 0.001
Desaturation	3.5 ± 5.4	13.2 ± 7.8	< 0.001
Hospitalization	4.1 ± 6.0	15.3 ± 8.4	< 0.001
Hypertension	3.9 ± 5.9	10.0 ± 8.1	< 0.001
Diabetes	4.1 ± 6.2	12.0 ± 7.3	< 0.001
Cancer status	4.3 ± 6.3	11.3 ± 7.0	0.003
Cardiac disease	4.4 ± 6.4	9.1 ± 7.2	0.043
Demographics data
Age 18–34 years	1.4 ± 2.8		< 0.001
Age 35–44 years	3.2 ± 5.0
Age 45–54 years	5.2 ± 5.6
Age 55–64 years	8.5 ± 9.1
Age > 64 years	10.0 ± 6.9
Delay between symptoms and LDCT
0–3 days	1.4 ± 3.6		0.003
4–7 days	4.4 ± 6.8
8–11 days	4.7 ± 6.2
> 11 days	7.1 ± 7.3

All significant results with a p < 0.05 have been highlighted in bold
Distribution of the CT-SS according to symptoms across age and delay between symptoms and LDCT. The continuous variables are presented as the mean value ± DS
COVID-19 coronavirus disease 2019, LDCT low-dose computed tomography, p value: Wilcoxon Mann–Whitney/Kruskal–Wallis test